Host CD8α+ and CD103+ dendritic cells prime transplant antigen-specific CD8+ T cells via cross-dressing
Bin Li
The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorChunni Lu
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorSara Oveissi
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorJing Song
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Department of Rheumatology, Second Military Medical University, Shanghai, China
Search for more papers by this authorKun Xiao
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorDamien Zanker
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Peter MacCallum Cancer Centre, Parkville, VIC, Australia
Search for more papers by this authorMubin Duan
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorJianxin Chen
College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
Search for more papers by this authorHuji Xu
Department of Rheumatology, Second Military Medical University, Shanghai, China
Search for more papers by this authorQuanming Zou
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorChao Wu
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorJonathan W Yewdell
Cellular Biology Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA
Search for more papers by this authorCorresponding Author
Weisan Chen
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Correspondence
Weisan Chen, La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia.
E-mail: [email protected]
and
Jonathan W Yewdell, Cellular Biology Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
E-mail: [email protected]
Search for more papers by this authorBin Li
The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorChunni Lu
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorSara Oveissi
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorJing Song
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Department of Rheumatology, Second Military Medical University, Shanghai, China
Search for more papers by this authorKun Xiao
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorDamien Zanker
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Peter MacCallum Cancer Centre, Parkville, VIC, Australia
Search for more papers by this authorMubin Duan
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Search for more papers by this authorJianxin Chen
College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
Search for more papers by this authorHuji Xu
Department of Rheumatology, Second Military Medical University, Shanghai, China
Search for more papers by this authorQuanming Zou
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorChao Wu
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, China
Search for more papers by this authorJonathan W Yewdell
Cellular Biology Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA
Search for more papers by this authorCorresponding Author
Weisan Chen
La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia
Correspondence
Weisan Chen, La Trobe Institute for Molecular Science, School of Molecular Science, La Trobe University, Bundoora, VIC, Australia.
E-mail: [email protected]
and
Jonathan W Yewdell, Cellular Biology Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.
E-mail: [email protected]
Search for more papers by this authorAbstract
The participation of dendritic cells (DCs) in CD8+ T-cell-mediated allograft rejection is a long-standing question of great clinical relevance for tissue transplantation. Here, we show that Batf3−/− mice demonstrate delayed allo-skin graft rejection and are deficient in priming allo-specific CD8+ T cells. Batf3−/− mouse priming is restored by transferring either purified CD8α+ or CD103+ DCs, demonstrating the critical role of these cells in alloreactivity. Using Db-restricted antiviral F5 transgenic T-cell receptor T cells, which we demonstrate are alloreactive with H-2Kd, we show that cross-dressing of CD8α+ and CD103+ primes CD8+ T-cell or allo-specific responses in vitro and in vivo. These findings suggest novel strategies for moderating tissue rejection based on interfering with DC cross-dressing or subsequent interaction with T cells.
Video Short
Host CD8α+ and CD103+ dendritic cells prime transplant antigen‐specific CD8+ T cells via cross‐dressing
by Li et al.Conflict of Interest
We declare that none of the authors have a competing interest.
Supporting Information
| Filename | Description |
|---|---|
| imcb12342-sup-0001-FigS1.tifTIFF image, 2.4 MB | Supplementary figure 1 |
| imcb12342-sup-0002-FigS2.tifTIFF image, 2.6 MB | Supplementary figure 2 |
| imcb12342-sup-0003-FigS3.tifTIFF image, 5 MB |
Supplementary figure 3 Supplementary figure 4 |
| imcb12342-sup-0004-FigS4.tifTIFF image, 3.1 MB |
Supplementary figure 4 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173: 4828–4837.
- 2Safinia N, Afzali B, Atalar K, Lombardi G, Lechler RI. T-cell alloimmunity and chronic allograft dysfunction. Kidney Int 2010; S2–12.
- 3Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010; 115: 3146–3157.
- 4Garrod KR, Liu FC, Forrest LE, Parker I, Kang SM, Cahalan MD. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity. J Immunol 2010; 184: 2329–2336.
- 5Smyth LA, Lechler RI, Lombardi G. Continuous acquisition of MHC: peptide complexes by recipient cells contributes to the generation of Anti-Graft CD8+ T Cell Immunity. Am J Transplant 2017; 17: 60–68.
- 6Zhuang Q, Liu Q, Divito SJ, et al. Graft-infiltrating host dendritic cells play a key role in organ transplant rejection. Nat Commun 2016; 7: 12623.
- 7den Haan JM, Lehar SM, Bevan MJ. CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685–1696.
- 8Belz GT, Shortman K, Bevan MJ, Heath WR. CD8α+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J Immunol 2005; 175: 196–200.
- 9del Rio ML, Rodriguez-Barbosa JI, Kremmer E, Forster R. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J Immunol 2007; 178: 6861–6866.
- 10Murphy TL, Tussiwand R, Murphy KM. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol 2013; 13: 499–509.
- 11Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 322: 1097–1100.
- 12Waithman J, Zanker D, Xiao K, et al. Resident CD8+ and Migratory CD103+ Dendritic Cells Control CD8 T Cell Immunity during Acute Influenza Infection. PLoS One2013; 8: e66136.
- 13Torti N, Walton SM, Murphy KM, Oxenius A. Batf3 transcription factor-dependent DC subsets in murine CMV infection: differential impact on T-cell priming and memory inflation. Eur J Immunol 2011; 41: 2612–2618.
- 14Edelson BT, Bradstreet TR, Hildner K, et al. CD8α+ dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity 2011; 35: 236–248.
- 15Broz ML, Binnewies M, Boldajipour B, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26: 638–652.
- 16Zhang Y, Chen G, Liu Z, et al. Genetic vaccines to potentiate the effective CD103+DC-mediated Cross-priming of Anti-tumor Immunity. J Immunol 2015; 194: 5937–5947.
- 17Atif SM, Nelsen MK, Gibbings SL, et al. Cutting edge: roles for Batf3-dependent APCs in the rejection of minor histocompatibility antigen-mismatched grafts. J Immunol 2015; 195: 46–50.
- 18Chandra J, Kuo PT, Hahn AM, Belz GT, Frazer IH. Batf3 selectively determines acquisition of CD8+ dendritic cell phenotype and function. Immunol Cell Biol 2017; 95: 215–223.
- 19Wei J, Waithman J, Lata R, et al. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. J Immunol 2010; 185: 6013–6022.
- 20Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 2000; 164: 2978–2986.
- 21Schmaler M, Broggi MA, Rossi SW. Transplantation of tail skin to study allogeneic CD4 T cell responses in mice. J Vis Exp 2014; e51724.
- 22Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996; 4: 565–571.
- 23Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature 2011; 471: 629–632.
- 24Sun T, Rojas OL, Li C, Ward LA, Philpott DJ, Gommerman JL. Intestinal Batf3-dependent dendritic cells are required for optimal antiviral T-cell responses in adult and neonatal mice. Mucosal Immunol 2017; 10: 775–788.
- 25Krueger PD, Kim TS, Sung SS, Braciale TJ, Hahn YS. Liver-resident CD103+ dendritic cells prime anti-viral CD8+ T cells in situ. J Immunol 2015; 194: 3213–3222.
- 26Smith AL, de St. Groth BF. Antigen-pulsed CD8α+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 1999; 189: 593–598.
- 27Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005; 23: 651–682.
- 28Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 2006; 176: 1447–1455.
- 29Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol 2006; 177: 6018–6024.
- 30Li L, Kim S, Herndon JM, et al. Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination. Proc Natl Acad Sci USA 2012; 109: 12716–12721.
- 31Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006; 25: 153–162.
- 32Fujimoto K, Karuppuchamy T, Takemura N, et al. A new subset of CD103+CD8α+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 2011; 186: 6287–6295.
- 33Cerovic V, Bain CC, Mowat AM, Milling SW. Intestinal macrophages and dendritic cells: what's the difference? Trends Immunol 2014; 35: 270–277.
- 34Hughes AD, Zhao D, Dai H, et al. Cross-dressed dendritic cells sustain effector T cell responses in islet and kidney allografts. J Clin Invest 2020; 130: 287–294.
- 35Ono Y, Perez-Gutierrez A, Nakao T, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance. Hepatology 2018; 67: 1499–1515.
- 36Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4−8+ T cells. Cell 1992; 71: 1205–1214.
- 37Mamalaki C, Norton T, Tanaka Y, et al. Thymic depletion and peripheral activation of class I major histocompatibility complex-restricted T cells by soluble peptide in T-cell receptor transgenic mice. Proc Natl Acad Sci USA 1992; 89: 11342–11346.
- 38Chen W, Masterman KA, Basta S, et al. Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 2004; 34: 194–199.
- 39Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000; 12: 83–93.
- 40Zanker D, Xiao K, Oveissi S, Guillaume P, Luescher IF, Chen W. An optimized method for establishing high purity murine CD8+ T cell cultures. J Immunol Methods 2013; 387: 173–180.
- 41Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171: 131–137.
- 42Hasenkrug KJ, Cory JM, Stimpfling JH. Monoclonal antibodies defining mouse tissue antigens encoded by the H-2 region. Immunogenetics 1987; 25: 136–139.
- 43Ozato K, Hansen TH, Sachs DH. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol 1980; 125: 2473–2477.
- 44Zanker D, Waithman J, Yewdell JW, Chen W. Mixed proteasomes function to increase viral peptide diversity and broaden antiviral CD8+ T cell responses. J Immunol 2013; 191: 52–59.
Citing Literature
Journal of the Australian and New Zealand Society for Immunology
